Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-060774

Options or other derivatives

  • Executive VP, Head of R&D acquired 13,800 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Ho Tony W Executive VP, Head of R&D 2021-10-15 Grant or award · Stock Option (Right to Buy) +13,800 13,800 D: show line 1 in the form
Loading xslF345X03/doc4.xml…